News for TYME Stock

Syros and Tyme Technologies Announce Stockholder Approval of Merger Syros and Tyme Technologies Announce Stockholder Approval of Merger Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results TYME Technologies, Inc. Announces Exploration of Strategic Options TYME Technologies, Inc. Announces Changes to its Board of Directors TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET TYME Appoints Frank L. Porfido as Chief Financial Officer TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium TYME Builds Leadership Team with Announcement of New CEO TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020